Objectives:

1. Describe the use of PD-L1 gene alterations as a surrogate genetic biomarker for an immune inflamed environment in DLBCL and in predicting response to PD-1 blockade therapy in relapsed/refractory DLBCL patients.
2. Describe how recently-acquired large genomic datasets will be interrogated to identify DLBCL clusters associated with unique immune signatures.
3. Describe the use of a genome-wide CRISPR/Cas9 screen to identify lymphoma-intrinsic molecules that regulate phagocytosis by macrophages in the context of CD47-SIRP-alpha axis blockade.